These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29424120)

  • 1. Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parameters.
    Mielke J; Woehling H; Jones B
    Pharm Stat; 2018 May; 17(3):231-247. PubMed ID: 29424120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design of clinical trials to support the switching and alternation of biosimilars.
    Faccin F; Tebbey P; Alexander E; Wang X; Cui L; Albuquerque T
    Expert Opin Biol Ther; 2016 Dec; 16(12):1445-1453. PubMed ID: 27666115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching.
    Declerck P; Bakalos G; Zintzaras E; Barton B; Schreitmüller T
    Clin Ther; 2018 May; 40(5):798-809.e2. PubMed ID: 29699853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
    Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
    Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.
    Druedahl LC; Kälvemark Sporrong S; Minssen T; Hoogland H; De Bruin ML; van de Weert M; Almarsdóttir AB
    PLoS One; 2022; 17(1):e0262537. PubMed ID: 35015783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
    Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar medicines - Review.
    Dos Reis C; Teixo R; Mendes F; Cruz RS
    Int J Risk Saf Med; 2016 Mar; 28(1):45-60. PubMed ID: 27176756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: State of Clinical and Regulatory Science.
    Klein AV; Wang J; Feagan BG; Omoto M
    J Pharm Pharm Sci; 2017; 20(1):332-348. PubMed ID: 29145936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.
    Cohen HP; Blauvelt A; Rifkin RM; Danese S; Gokhale SB; Woollett G
    Drugs; 2018 Mar; 78(4):463-478. PubMed ID: 29500555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
    Schiestl M; Zabransky M; Sörgel F
    Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Opportunities and challenges of extrapolation for biosimilars].
    Weise M; Wolff-Holz E
    Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stakeholders discuss biosimilar naming, substitution.
    Traynor K
    Am J Health Syst Pharm; 2014 Mar; 71(6):446-7. PubMed ID: 24589534
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
    Mysler E; Azevedo VF; Danese S; Alvarez D; Iikuni N; Ingram B; Mueller M; Peyrin-Biroulet L
    Drugs; 2021 Nov; 81(16):1859-1879. PubMed ID: 34705255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
    Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
    MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Analysis of Biosimilar Switching Studies.
    Chow SC; Lee SJ
    Pharmaceut Med; 2019 Oct; 33(5):379-388. PubMed ID: 31933227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching Between Epoetins: A Practice in Support of Biosimilar Use.
    D'Amore C; Da Cas R; Rossi M; Traversa G
    BioDrugs; 2016 Feb; 30(1):27-32. PubMed ID: 26728875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
    Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
    Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment.
    Dong XC; Weng YT; Tsong Y
    J Biopharm Stat; 2017; 27(2):220-232. PubMed ID: 28060570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.